PPARgamma activation induces CD36 expression and stimulates foam cell like changes in rVSMCs.
The purpose of the present study was to determine the role of peroxisome proliferator-activated receptor gamma (PPARgamma) activation in smooth muscle cell (SMC) derived form cell formation. Wild and mutant type PPARgamma were delivered by adenovirus then activated with troglitazone. The result of Oil Red O staining and FACS analysis showed that PPARgamma activation induced lipid accumulation in rVSMCs. Furthermore, PPARgamma activation reduced SMC marker genes such as alpha-actin while induced adipocyte differentiation marker genes and lipid metabolism-related genes as evidenced by RT-PCR and fluorescent immunocytochemistry. All these data demonstrate that PPARgamma activation can drive foam cell like change in rVSMCs. Our results strongly suggest that PPARgamma expression induces CD36 expression and adipocyte differentiation gene activation in the process of atherosclerosis and might be one of the crucial events in SMC derived foam cell formation.
Lim
Hyun-Joung
HJ
Division of Cardiovascular Diseases, Center for Biomedical Sciences, NIH, Republic of Korea.
Lee
Seahyoung
S
Lee
Kuy-Sook
KS
Park
Jin-Hee
JH
Jang
Yangsoo
Y
Lee
Eun Jig
EJ
Park
Hyun-Young
HY
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D000199:Actins / Q000235:genetics; D052242:Adiponectin / Q000235:genetics; D000818:Animals; D018955:CD36 Antigens / Q000235:genetics / Q000378:metabolism*; D002478:Cells, Cultured; D002839:Chromans / Q000494:pharmacology; D011416:Complement Factor D / Q000235:genetics; D050556:Fatty Acid-Binding Proteins / Q000235:genetics; D005487:Foam Cells / Q000166:cytology / Q000378:metabolism*; D015870:Gene Expression / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000494:pharmacology; D050356:Lipid Metabolism / Q000187:drug effects; D051379:Mice; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D032389:Myocytes, Smooth Muscle / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D047493:PPAR alpha / Q000235:genetics; D047495:PPAR gamma / Q000819:agonists / Q000235:genetics / Q000378:metabolism*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D045162:Thiazolidinediones / Q000494:pharmacology; D014162:Transfection; D000077288:Troglitazone; D014335:Tropomyosin / Q000235:genetics
C477819:15-deoxyprostaglandin J2; D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters; D000199:Actins; D052242:Adiponectin; D018955:CD36 Antigens; D002839:Chromans; D050556:Fatty Acid-Binding Proteins; D007004:Hypoglycemic Agents; D047493:PPAR alpha; D047495:PPAR gamma; D010982:Platelet-Derived Growth Factor; D045162:Thiazolidinediones; D014335:Tropomyosin; D011416:Complement Factor D; D000077288:Troglitazone; D015230:Prostaglandin D2